BioLife Solns Stock (NASDAQ:BLFS), Trade Ideas

BioLife Solns

BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.

BioLife Solutions

Earnings

News

Small Cap

Markets

Trading Ideas

BLFS

Boston Scientific (NYSE: BSX) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.47 per share a year ago. These figures are adjusted for non-recurring items.

Boston Scientific Q1 Earnings and Revenues Top Estimates

Meta Platforms - logo

Short Ideas

Insider Trades

PSTG

SCVL

Meta Platforms, Pure Storage And 2 Other Stocks Insiders Are Selling

Long Ideas

Pre-Market Outlook

Although U.S. stocks closed mixed on Monday, there were a few notable insider trades.

Over $1M Bet On Carnival? Check Out These 3 Stocks Insiders Are Buying

BioLife Solutions Inc

The Nasdaq 100 closed lower by around 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades.
When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.
Below is a look at a few recent notable insider sales. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading" id="h-meta-platforms">Meta Platforms</h3>
<ul>
<li>The Trade: Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) Chief Legal Officer Jennifer Newstead <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 585 shares</a> at an average price of $498.59. The insider received around $291,675 from selling those shares.</li>
<li>What's Happening: Meta Platforms announced new features in its Meta AI assistant, including expanded availability and real-time image creation capabilities.</li>
<li>What Meta Platforms Does: Meta is the world&#8217;s largest online social network, with nearly 4 billion family of apps monthly active users.</li>
</ul>
Have a look at our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<h3 class="wp-block-heading" id="h-pure-storage">Pure Storage</h3>
<ul>
<li>The Trade: Pure Storage, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) Chief Revenue Officer Dan Fitzsimons <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 29,283 shares</a> at an average price of $52.14. The insider received around $1.53 million from selling those shares.</li>
<li>What's Happening: On April 11, Susquehanna analyst Mehdi Hosseini maintained Pure Storage with a Positive and raised the price target from $45 to $65.</li>
<li>What Pure Storage Does: Pure Storage Inc is a U.S.-based company that provides an enterprise data storage platform that transforms business through a dramatic increase in performance and reduction in complexity and costs.</li>
</ul>
<h3 class="wp-block-heading" id="h-shoe-carnival">Shoe Carnival</h3>
<ul>
<li>The Trade: Shoe Carnival, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCVL#NASDAQ">SCVL</a>) Director Andrea R. Guthrie <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 2,467 shares</a> at an average price of $32.46. The insider received around $80,079 from selling those shares.</li>
<li>What's Happening: On March 21, Shoe Carnival reported a fourth-quarter FY23 sales decline of 3.7% year-on-year to $280.17 million, marginally missing the analyst consensus estimate of $280.27 million.</li>
<li>What Shoe Carnival Does: Shoe Carnival Inc is a family footwear retailer that offers a broad assortment of dress, casual and athletic footwear for men, women, and children with an emphasis on national name brands such as Nike, Skechers, Adidas, Puma, HEYDUDE, Converse, Vans, and Crocs.</li>
</ul>
<h3 class="wp-block-heading" id="h-biolife-solutions">BioLife Solutions</h3>
<ul>
<li>The Trade: BioLife Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) Chief Marketing Officer Todd Berard <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 10,000 shares</a> at an average price of $15.67. The insider received around $156,700 from selling those shares.</li>
<li>What's Happening: BioLife Solutions announceD the divestiture of its Stirling Freezer Business.</li>
<li>What BioLife Solutions Does: BioLife Solutions Inc is active in the healthcare segment.</li>
</ul>

Check This Out: <a href="https://www.benzinga.com/news/earnings/24/04/38329059/netflix-procter-gamble-and-3-stocks-to-watch-heading-into-friday">Netflix, Procter &amp; Gamble And 3 Stocks To Watch Heading Into Friday</a>

BioLife Solutions Completes Divestiture Of Its Stirling Freezer Business; Says Sale Is Expected To Immediately Eliminate 'Several Million Dollars' Of Quarterly Cash Burn And Removes Product Warranty Liabilities, Which Totaled $7.5M As Of December 31, 2023

Jefferies analyst Matthew Stanton initiates coverage on BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Buy rating and announces Price Target of $22.

Price Target

Initiation

Analyst Ratings

Jefferies Initiates Coverage On BioLife Solns with Buy Rating, Announces Price Target of $22

WIIM

BioLife Solutions shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results.

Guidance

BioLife Solutions Expects 2024 Revenue $95.5M-$100M Excluding Freezer Business

BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) reported its Q4 earnings results on Thursday, February 29, 2024 at 04:00 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
BioLife Solns beat estimated earnings by 38.0%, reporting an EPS of $-0.21 versus an estimate of $-0.34.
Revenue was down $11.53 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.05 which was followed by a 4.0% drop in the share price the next day.
Here's a look at BioLife Solns's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.38</td>
<td>-0.20</td>
<td>-0.21</td>
<td>-0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.33</td>
<td>-0.24</td>
<td>-0.27</td>
<td>-0.19</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>32.94M</td>
<td>43.86M</td>
<td>42.94M</td>
<td>43.28M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>33.33M</td>
<td>39.51M</td>
<td>37.70M</td>
<td>44.26M</td>
</tr>
</tbody>
</table>

To track all earnings releases for BioLife Solns <a href="https://www.benzinga.com/quote/BLFS/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: BioLife Solns Q4 Earnings

BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) reported quarterly losses of $(0.210) per share which beat the analyst consensus estimate of $(0.340) by 38.24 percent. The company reported quarterly sales of $32.732 million which missed the analyst consensus estimate of $33.399 million by 2.00 percent. This is a 26.04 percent decrease over sales of $44.259 million the same period last year.

Earnings Beats

Earnings Misses

BioLife Solns Q4 2023 Adj EPS $(0.210) Beats $(0.340) Estimate, Sales $32.732M Miss $33.399M Estimate

BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) is set to give its latest quarterly earnings report on Thursday, 2024-02-29. Here's what investors need to know before the announcement.
Analysts estimate that BioLife Solns will report an earnings per share (EPS) of $-0.34. 
BioLife Solns bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.05, which was followed by a 3.86% drop in the share price the next day.
Here's a look at BioLife Solns's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.38</td>
<td>-0.20</td>
<td>-0.21</td>
<td>-0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.33</td>
<td>-0.24</td>
<td>-0.27</td>
<td>-0.19</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-28.999999999999996%</td>
<td>-2.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709139665_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of BioLife Solns were trading at $17.11 as of February 27. Over the last 52-week period, shares are down 26.02%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/BLFS/earnings">To track all earnings releases for BioLife Solns visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For BioLife Solns

BioLife Solutions shares are trading higher. The company issued preliminary Q4 and FY23 revenue guidance.

BioLife Solutions Sees Prelim FY23 Revenue $143.3M Vs $144.37M Est.

BioLife Solutions Sees Prelim Q4 Revenue $32.7M Vs $33.82M Est.

BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) reported its Q3 earnings results on Thursday, November 9, 2023 at 04:00 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
BioLife Solns beat estimated earnings by 13.16%, reporting an EPS of $-0.33 versus an estimate of $-0.38.
Revenue was down $7.42 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.04 which was followed by a 28.71% drop in the share price the next day.
Here's a look at BioLife Solns's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.20</td>
<td>-0.21</td>
<td>-0.17</td>
<td>-0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.24</td>
<td>-0.27</td>
<td>-0.19</td>
<td>-0.15</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>43.86M</td>
<td>42.94M</td>
<td>43.28M</td>
<td>42.06M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>39.51M</td>
<td>37.70M</td>
<td>44.26M</td>
<td>40.75M</td>
</tr>
</tbody>
</table>

To track all earnings releases for BioLife Solns <a href="https://www.benzinga.com/quote/BLFS/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BioLife Solns: Q3 Earnings Insights

Biolife Q3 2023 EPS $(0.67) Misses $(0.38) Estimate, Revenue $33.3B Beats $33M Estimate

Casdin Partners Master Fund LP, 10% Owner at BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>), reported a large insider buy on October 23, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000834365/000091957423005783//Archives/edgar/data/834365/000091957423005783/0000919574-23-005783-index.htm">U.S. Securities and Exchange Commission</a> on Monday showed that LP purchased 927,165 shares of BioLife Solns. The total transaction amounted to $10,374,976. 
BioLife Solns shares are trading up 4.3% at $10.18 at the time of this writing on Tuesday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000834365">Check Out The Full List Of BioLife Solns's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10% Owner of BioLife Solns Makes $10.37M Buy

Management

BioLife Solutions Names Roderick de Greef As CEO, Chairman Of Board

Craig-Hallum analyst Matt Hewitt maintains BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Buy and lowers the price target from $29 to $23.

Craig-Hallum Maintains Buy on BioLife Solns, Lowers Price Target to $23

TD Cowen analyst Max Masucci maintains BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Outperform and lowers the price target from $29 to $25.

TD Cowen Maintains Outperform on BioLife Solns, Lowers Price Target to $25

<h3>Gainers</h3>
<ul>
<li>Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) stock moved upwards by 90.3% to $7.29 during Wednesday's regular session. Trading volume for Tango Therapeutics's stock is 56.0 million as of 13:30 EST. This is 26711.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $644.9 million. As per the press release, Q2 earnings came out 2 days ago. </li>
<li>Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) shares rose 76.16% to $3.4. As of 13:30 EST, this security is trading at a volume of 22.2 million shares, making up 7273.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.5 million. </li>
<li>Decibel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBTX#NASDAQ">DBTX</a>) stock moved upwards by 75.98% to $4.91. Trading volume for this security as of 13:30 EST is 5.0 million, which is 17771.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $122.8 million. </li>
<li>Renovaro Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) stock increased by 68.23% to $1.43. Trading volume for this security as of 13:30 EST is 30.7 million, which is 3172.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $91.0 million. </li>
<li>Science 37 Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCE#NASDAQ">SNCE</a>) shares increased by 43.09% to $0.39. The current volume of 20.5 million shares is 4652.2% of Science 37 Hldgs's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $45.1 million. The company's, Q2 earnings came out yesterday. </li>
<li>Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) shares rose 33.58% to $2.65. As of 13:30 EST, this security is trading at a volume of 3.0 million shares, making up 290.5% of its average full-day volume over the last 100 days. The company's market cap stands at $251.5 million. As per the press release, Q2 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares fell 64.4% to $0.69 during Wednesday's regular session. As of 13:30 EST, Palisade Bio's stock is trading at a volume of 3.6 million, which is 1120.1% of its average full-day volume over the last 100 days. The company's market cap stands at $4.6 million. </li>
<li>Mallinckrodt (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MNK#AMEX">MNK</a>) stock declined by 35.18% to $0.94. The current volume of 2.1 million shares is 45.6% of Mallinckrodt's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $12.3 million. </li>
<li>BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) shares decreased by 28.2% to $13.21. As of 13:30 EST, BioLife Solns's stock is trading at a volume of 1.5 million, which is 463.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $574.2 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Seer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEER#NASDAQ">SEER</a>) shares fell 26.94% to $3.4. Trading volume for Seer's stock is 368.0K as of 13:30 EST. This is 147.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $217.0 million. The company's, Q2 earnings came out yesterday. </li>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) shares declined by 24.96% to $0.3. As of 13:30 EST, this security is trading at a volume of 3.2 million shares, making up 229.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $8.9 million. </li>
<li>Infinity Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INFI#NASDAQ">INFI</a>) shares decreased by 24.51% to $0.1. As of 13:30 EST, this security is trading at a volume of 7.7 million shares, making up 282.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $8.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BNTC

DBTX

INFI

PALI

PSTX

RENB

SEER

SNCE

TNGX

VVOS

12 Health Care Stocks Moving In Wednesday's Intraday Session

BioLife Solutions shares are trading lower after the company reported worse-than-expected Q2 financial results and issued FY23 revenue guidance below estimates.

Lake Street analyst Thomas Flaten maintains BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Buy and lowers the price target from $34 to $25.

Lake Street Maintains Buy on BioLife Solns, Lowers Price Target to $25

BioLife Solutions, Inc. (BLFS) Q4 2024 Earnings Call Transcript

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioLife Solutions (BLFS – Research Report), Cooper...

Analysts' Opinions Are Mixed on These Healthcare Stocks: BioLife Solutions (BLFS), Cooper Co (COO) and PTC Therapeutics (PTCT)

Northland Securities analyst Carl Byrnes maintained a Buy rating on BioLife Solutions (BLFS – Research Report) today and set a price target of $26....

BioLife Solutions (BLFS) Receives a Buy from Northland Securities

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avadel Pharmaceuticals (AVDL – Research Report), Bio...

Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), BioLife Solutions (BLFS) and Inotiv (NOTV)

BioLife Solutions Inc (BLFS) has disclosed a new risk, in the Natural and Human Disruptions category. BioLife Solutions Inc. faces significant risk...

A New Cause for Concern: BioLife Solutions Inc Adds a New Natural and Human Disruptions Risk

BioLife Solutions (BLFS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Stanton from...

Buy Rating on BioLife Solutions: Focused Growth and Market Leadership Post-Divestiture

BioLife Solutions divest stirling freezer business to reduce cash burn

Lake Street analyst Thomas Flaten maintained a Buy rating on BioLife Solutions (BLFS – Research Report) today and set a price target of $20.00. The...

BioLife Solutions (BLFS) Receives a Buy from Lake Street

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioLife Solutions (BLFS – Research Report) and Alime...

Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Alimera (ALIM)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioLife Solutions (BLFS – Research Report) and Intra...

Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Intra-Cellular Therapies (ITCI)

ALIM

AVDL

ITCI

NOTV

PTCT

Press Releases

BioLife Solutions Reports First Quarter 2023 Financial Results

BioLife Solutions Launches the IntelliRate™ i67C Liquid Nitrogen (LN2) Controlled-Rate Freezer

BioLife Solutions Receives College of American Pathologists CAP-BAP Accreditation for All SciSafe® U.S. Biostorage Facilities

BioLife Solutions to Provide Second Quarter 2023 Financial Results and Business Update on August 8, 2023

BioLife Solutions Reports Second Quarter 2023 Financial Results, Updates Full Year 2023 Guidance and Provides Pro Forma First Half 2023 Financial Profile Excluding Freezer Business

BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue

BioLife Solutions to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update on February 29, 2024

BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results

BioLife Solutions to Present at TD Cowen and Key Bank Investor Conferences

BioLife Solutions Announces the Divestiture of its Stirling Freezer Business

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

Conduit Pharmaceuticals Inc. - Common Stock

Conduit Pharmaceuticals

ChromaDex

Codexis

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share